Over the Counter, and Distribution Channel [Pharmacies, Grocery Stores, Vitamin and Health Food Stores, Online Pharmacies, and Others] - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4403128
  • Report
  • Region: Global
  • 220 pages
  • Allied Analytics LLP
1 of 4
Over the counter (OTC) drugs are non-prescription medicines, which are sold directly to consumers without any prescription from doctors and other healthcare professionals. The OTC drugs are regulated by governmental bodies to ensure that the ingredients used are safe and effective for use without a physician’s supervision. These drugs are regulated by active pharmaceutical ingredients (APIs) not final product. Dietary supplements are intended to provide nutrients to increase the quantity of consumption or provide non-nutrient chemicals that have biologically beneficial effects to users. These supplements are available across all distribution channels such as pharmacies, grocery stores, shopping marts, online pharmacies, and other retailers. The global over the counter (OTC) drugs & dietary supplements market was valued at $223 billion in 2016, and is expected to reach at $335 billion by 2023, registering a CAGR of 5.9% from 2017 to 2023.

The global over the counter (OTC) drugs & dietary supplements market is driven by improvement in lifestyle & ageing of baby boomers, rise in consumer awareness related to preventative healthcare, and proliferation of distribution channels. In addition, increase in trend of self-directed consumers and self-medication for the treatment of primary health conditions have fueled the market growth. However, stringent regulations by FDA and other governing bodies related to the safety & efficacy of OTC medications have delayed the approval restricting the market growth. Furthermore, minors, i.e. individuals under 18 years of age, are restricted to buy certain medications, which consist addictive chemicals, impeding the market growth.

The global over the counter (OTC) drugs & dietary supplements market is segmented based on category, dosage form, product, distribution channel, and geography. Based on category, it is divided into vitamin and dietary supplements, cough & cold products, analgesics, gastrointestinal products, sleep aids, otic products, wart removers, mouth care products, ophthalmic products, botanicals, antacids, smoking cessation products, feminine care, and others. On the basis of dosage form, it is classified into tablets, hard capsules, powders, ointments, soft capsules, liquids, and others. Based on product, it is categorized into branded and generic drugs. Based on distribution channel, it is divided into pharmacies, grocery stores, vitamin & health food stores, online pharmacies, and others.

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the high consumer base especially for dietary supplements as consumers are more health conscious. However, Asia-Pacific is expected to emerge as a lucrative area for market players, due to increase in disposable income along with a shift in the consumer preference towards self-medication, improvement in healthcare facilities, and rapid development of economic conditions.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global over the counter (OTC) drugs & dietary supplements market along with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analyses of factors that drive and restrict the market growth are provided in the report.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps in understanding the trending products across the various regions.
Key market players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Category

Vitamin & Dietary Supplements
Cough & Cold Products
Analgesics
Gastrointestinal Products
Sleep Aids
Otic Products
Wart Removers
Mouth Care Products
Ophthalmic Products
Botanicals
Antacids
Smoking Cessation Products
Feminine Care
Others

By Dosage Form

Tablets
Hard Capsules
Powders
Ointments
Soft Capsules
Liquids
Others

By Product

Branded Drugs
Generic Drugs

By Distribution Channel

Pharmacies
Grocery Stores
Vitamin & Health Food Stores
Online Pharmacy
Others

BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Turkey
South Africa
Saudi Arabia
Rest of LAMEA

KEY PLAYERS PROFILED

Pfizer Inc.
Novartis International AG.
Roche Holding AG
Merck & Co., Inc.
Sanofi S.A
Johnson & Johnson
Gilead Sciences
GlaxoSmithKline plc.
Bayer Healthcare AG
AstraZeneca plc.

The other players in the value chain include (profiles not included in the report)

Alacer Corp
Alcon Inc.
Alfresa Pharma Corporation
Alkalon A/S
Alliance Healthcare
Allergan, Plc.
Reckitt Benckiser Plc.
Bausch & Lomb
AbbVie Inc.
The Colgate-Palmolive Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Improvement in lifestyle and age related diseases
3.6.1.2. The rise in self-directed consumer
3.6.1.3. Growing awareness regarding general health concerns and advancements in healthcare industry

3.6.2. Restraints

3.6.2.1. Stringent regulatory policies by governing bodies
3.6.2.2. Lack of seamless reclassification of drugs from prescription medicines to over the counter drugs

3.6.3. Opportunities

3.6.3.1. Increasing R&D expenditure and funding from the public & private sector

CHAPTER 4 OVER THE COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS MARKET, BY CATEGORIES

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VITAMIN AND DIETARY SUPPLEMENTS (VDS)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. COUGH & COLD PRODUCTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANALGESICS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. GASTROINTESTINAL PRODUCTS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. SLEEP AIDS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTIC PRODUCTS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. WART REMOVERS

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

4.9. MOUTH CARE PRODUCTS

4.9.1. Key market trends
4.9.2. Growth factors and opportunities
4.9.3. Market size and forecast

4.10. OPHTHALMIC PRODUCTS

4.10.1. Key market trends
4.10.2. Growth factors and opportunities
4.10.3. Market size and forecast

4.11. BOTANICALS

4.11.1. Key market trends
4.11.2. Growth factors and opportunities
4.11.3. Market size and forecast

4.12. ANTACIDS

4.12.1. Key market trends
4.12.2. Growth factors and opportunities
4.12.3. Market size and forecast

4.13. SMOKING CESSATION PRODUCTS

4.13.1. Key market trends
4.13.2. Growth factors and opportunities
4.13.3. Market size and forecast

4.14. FEMININE CARE

4.14.1. Key market trends
4.14.2. Growth factors and opportunities
4.14.3. Market size and forecast

4.15. OTHERS

4.15.1. Key market trends
4.15.2. Growth factors and opportunities
4.15.3. Market size and forecast

CHAPTER 5 OVER THE COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS MARKET, BY DOSAGE FORMS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TABLETS

5.2.1. Market size and forecast

5.3. HARD CAPSULES

5.3.1. Market size and forecast

5.4. POWDERS

5.4.1. Market size and forecast

5.5. OINTMENTS

5.5.1. Market size and forecast

5.6. SOFT CAPSULES

5.6.1. Market size and forecast

5.7. LIQUIDS

5.7.1. Market size and forecast

5.8. OTHERS

5.8.1. Market size and forecast

CHAPTER 6 OVER THE COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS, BY PRODUCT TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. BRANDED

6.2.1. Market size and forecast

6.3. GENERICS

6.3.1. Market size and forecast

CHAPTER 7 OVER THE COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS MARKET, BY DISTRIBUTION CHANNEL

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. PHARMACIES

7.2.1. Market size and forecast

7.3. VITAMIN AND HEALTH FOOD STORES

7.3.1. Market size and forecast

7.4. ONLINE PHARMACY

7.4.1. Market size and forecast

7.5. GROCERY STORES

7.5.1. Market size and forecast

7.6. OTHERS

7.6.1. Market size and forecast

CHAPTER 8 OVER THE COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Turkey market size and forecast
8.5.3.4. Saudi Arabia market size and forecast
8.5.3.5. South Africa market size and forecast
8.5.3.6. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. PFIZER INC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. NOVARTIS INTERNATIONAL AG

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. ROCHE HOLDING AG

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. MERCK & CO., INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. SANOFI S.A

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. JOHNSON & JOHNSON

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. GILEAD SCIENCES

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. GLAXOSMITHKLINE PLC

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. BAYER HEALTHCARE AG

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. ASTRAZENECA PLC

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll